CSS
VYNE icon

Cubist Systematic Strategies’s VYNE Therapeutics VYNE Stock Holding History

Cubist Systematic Strategies’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,746
Closed -$426K – 3196
2021
Q2 		$426K Buy
+6,746
New +$534K ﹤0.01% 2113
2021
Q1 		– Sell
-354
Closed -$40K – 2988
2020
Q4 		$40K Buy
354
+260
+277% +$32.7K ﹤0.01% 2482
2020
Q3 		$11K Sell
94
-2
-2% -$233 ﹤0.01% 2429
2020
Q2 		$12K Buy
96
+7
+8% +$948 ﹤0.01% 2335
2020
Q1 		$17K Buy
+89
New +$27.9K ﹤0.01% 2072

Other funds holding VYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cubist Systematic Strategies's VYNE Position: Q3 2021 in Review

Cubist Systematic Strategies sold out of VYNE Therapeutics (VYNE) in Q3 2021, closing a stake of 6,746 shares — an estimated $426K sold.

Cubist Systematic Strategies first reported a position in VYNE in Q1 2020 and held it in 5 quarters. The position peaked at $426K in Q2 2021. 64 funds tracked by Wall St. Rank hold VYNE as of Q3 2021.

  • Cubist Systematic Strategies reported no remaining VYNE Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Cubist Systematic Strategies sold 6,746 VYNE Therapeutics shares in Q3 2021, an estimated $426K.
  • Cubist Systematic Strategies first reported a position in VYNE Therapeutics in Q1 2020 and held it in 5 quarters.
  • Cubist Systematic Strategies's VYNE Therapeutics position peaked at $426K in Q2 2021.
  • 64 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2021.

Based on Cubist Systematic Strategies's 13F filing for Q3 2021, filed 15 Nov 2021.